Last updated: 2026-09-06 01:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
AnaptysBio, Inc. (ANAB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $56,79, with a market capitalization of $1,65B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,11 to $73,30. This page covers its latest market performance, valuation, price trends and company information.
$1,65B | |
$56,84 | |
$134,00 | |
$10,00 | |
$57,46 | |
967,22K | |
-- | |
-- | |
$73,30 | |
$17,11 | |
-- | |
-- |
AnaptysBio, Inc. (ANAB) last closed at $57,46 as of 2026-09-04 23:31:00, unchanged from the previous close of $57,46.
During the latest regular trading session, ANAB traded between $10,00 and $134,00, with a volume of 967,22K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, AnaptysBio, Inc. (ANAB) moved from $55,83 to $56,79, representing a gain of 1,72% ($0,96).
The stock traded between $55,69 and $58,94 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 549,83 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 70,6%
ANAB is currently trading at $56,79, placing it 70,6% of the way from its 52-week low of $17,11 to its 52-week high of $73,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 104 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of AnaptysBio, Inc. (ANAB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.